Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -124.0%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7807 | $15768 | $8M | $17M | $25M | $68M | $44M | $15M | $9M | $22M | $18M |
| Enterprise Value | $-8465061 | $-8457100 | $472568 | $3M | $10M | $58M | $33M | $11M | $4M | $18M | $11M |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 88.17 | — | — | 43.81 | 15.10 | 9.37 | 215.60 | — |
| P/B Ratio | 0.00 | 0.00 | 0.23 | 0.50 | 0.53 | 1.05 | 0.55 | 1.39 | 0.85 | 2.51 | 1.34 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 15.96 | — | — | 33.46 | 10.94 | 4.21 | 176.13 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -0.1% | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | — | — | — | -11374.1% | — | — | -1323.9% | -715.6% | -782.6% | -11966.0% | — |
| Net Profit Margin | — | — | — | -10.2% | — | — | -2799.9% | -585.0% | -520.0% | -12177.0% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -124.0% | -124.0% | -21.5% | -0.0% | -38.6% | -25.4% | -61.8% | -53.5% | -53.1% | -110.8% | -106.3% |
| ROA | -96.6% | -96.6% | -17.8% | -0.0% | -34.7% | -23.9% | -56.8% | -39.7% | -36.0% | -83.7% | -94.3% |
| ROIC | -153.2% | -153.2% | -36.0% | -63.3% | -38.7% | -21.6% | -26.1% | -85.6% | -111.9% | -159.2% | -196.0% |
| ROCE | -128.1% | -128.1% | -31.4% | -52.6% | -39.8% | -24.5% | -28.8% | -63.4% | -72.7% | -100.7% | -61.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.88 | -0.22 | -0.41 | -0.31 | -0.16 | -0.13 | -0.38 | -0.47 | -0.46 | -0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -678.28 | -678.28 | -16.19 | -9.13 | -323.78 | -83.71 | -511.52 | -34.89 | -617.78 | -495.65 | -1183.17 |
Net cash position: cash ($9M) exceeds total debt ($243996)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | 1.27 | 2.23 | 2.20 | 4.71 | 11.41 | 19.14 | 2.34 | 2.57 | 1.96 | 11.70 |
| Quick Ratio | 1.27 | 1.27 | 2.23 | 2.20 | 4.71 | 11.41 | 19.14 | 2.76 | 2.33 | 1.96 | 17.84 |
| Cash Ratio | 1.23 | 1.23 | 2.14 | 2.15 | 4.55 | 11.11 | 18.66 | 1.80 | 1.56 | 0.97 | 11.51 |
| Asset Turnover | — | — | — | 0.00 | — | — | 0.01 | 0.07 | 0.07 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 182.50 | 544.95 | 271.19 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2400 | $163978 | $110666 | $90405 | $87840 | $57500 | $9683 | $7102 | $4728 | $2877 |
Imminent liquidity depletion
As reported in financial statements, Purple Biotech's ROIC has remained consistently negative, bottoming out at -61.8% in 2026Q1, which underscores the company's inability to generate productive returns on its R&D investments while operating as a pre-revenue entity focused entirely on clinical trial development.
The persistent negative ROIC reflects the structural reality of a biotech firm where capital is consumed by high-burn clinical activities rather than deployed into revenue-generating assets. Investors should monitor whether future clinical data readouts can justify this capital destruction by establishing a clear path to commercialization.
Based on the most recent quarterly data, the company's current ratio has fluctuated between 1.22 and 2.88, yet the absolute cash position of $8.7 million suggests a narrowing runway that warrants further investigation into the firm's ability to fund operations without immediate dilutive financing.
While the current ratio appears superficially adequate, it masks the reality that the company lacks the internal cash generation to sustain its current burn rate. The volatility in the quick ratio suggests that the company's liquidity is highly sensitive to the timing of clinical trial payments and potential capital raises.
According to recent SEC filings, Purple Biotech maintains a negligible debt-to-equity ratio, often hovering near 0.01, which indicates that management has prioritized equity-based funding over debt, likely to avoid the restrictive covenants that would otherwise threaten the firm's survival during its pre-revenue phase.
The lack of meaningful debt is a prudent choice for a clinical-stage entity, yet it shifts the entire burden of financing onto shareholders. This reliance on equity suggests that the company's financial flexibility is entirely dependent on market sentiment toward its oncology pipeline rather than its balance sheet strength.
Based on the provided financial data, the most commonly misapplied metric for Purple Biotech is the Price-to-Earnings ratio, which is fundamentally irrelevant for a pre-revenue firm and obscures the binary nature of the company's clinical-stage assets by suggesting a valuation based on non-existent earnings.
Investors should instead focus on the 'cash-out' date and the net present value of the clinical pipeline, as traditional multiples fail to capture the value of the CEACAM1 and NT219 programs. Relying on P/E or EV/EBITDA in this context may lead to a significant mispricing of the company's true risk-reward profile.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PPBT stock.
Purple Biotech Ltd.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Purple Biotech Ltd.'s return on equity (ROE) is -124.0%. The historical average is -61.6%.
Based on historical data, Purple Biotech Ltd. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.